Strides Pharma Science has been slapped with a warning letter from the US Food and Drug Administration over problems at its manufacturing plant in the western Indian city of Puducherry. But the firm, which has enjoyed a relatively strong regulatory compliance track record compared with some of its Indian pharmaceutical peers, said the notice will not affect its earnings guidance of 20% growth in US sales for the financial year to 31 March 2020.
Strides founder and managing director Arun Kumar stated in May that the company was looking at 20% growth in year-on-year sales in fiscal 2020 from the US